MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Other Non-Cash Items
Other non-cash adjustments that reconcile net income to operating cash flow.
MAIA Biotechnology, Inc.AMEX: MAIA
Other Non-Cash Items · Q1 FY2026 · quarter ended Mar 2026
Other non-cash items declines year over year
Q1 FY2026 other non-cash items of $211.3K (cash outflow) fell 74.4% year over year, ahead of the -98.1% change in trailing-twelve-month other non-cash items.
Context
- Other non-cash items increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -74.4% holds above the trailing-twelve-month pace of -98.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Non-Cash Items history
USD · from the cash flow
- Latest · FY2025
- (579.4K) USD
- Year-over-year change
- -108.4%
| Period | Period end | Other Non-Cash Items | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (579.4K) | -108.4% |
| FY2024 | 2024-12-31 | 6.88M | +1205.8% |
| FY2023 | 2023-12-31 | 526.53K | -47.4% |
| FY2022 | 2022-12-31 | 1M | -78.3% |
| FY2021 | 2021-12-31 | 4.61M | — |
Other Non-Cash Items vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 other non-cash items of $35.29K is the smallest of the 7 companies compared; the peer median is $331.65K.
- Its year-over-year change of -98.1% is the lowest of 6, against a peer median of +141.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $34.17M | — | +95.2% | — | |
| LTM Dec 2025 | $27.2M | +141.4% | — | 102.4% | |
| LTM Mar 2026 | $11.33M | +573.0% | +115.7% | — | |
| LTM Mar 2026 | $515.31K | +296.3% | -46.5% | — | |
| LTM Mar 2026 | $148K | -96.6% | — | — | |
| LTM Mar 2026 | $145K | -85.0% | — | 9.7% | |
| LTM Mar 2026 | $35.29K | -98.1% | — | — | |
| Peer median (excluding MAIA) | $331.65K | +141.4% | +95.2% | 56.1% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.72M | 2.32M | 3.09M | 1.91M | 2.63M |
| Change in Working Capital | 1.13M | 352.78K | 3.09M | (1.24M) | 1.5M |
| Accounts Receivables | 0 | (269.4K) | 158.41K | 56.81K | 80.41K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 805.52K | 211.35K | 471.9K | (118.83K) | 519.72K |
| Other Working Capital | 320.23K | 410.83K | 2.46M | (1.18M) | 899.19K |
| Other Non-Cash Items | 4.61M | 1M | 526.53K | 6.88M | (579.4K) |
| Operating Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 7.43M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 5.74M | 13.97M | 11.42M | 18.75M | 18.52M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 860.43K | (1.5M) | (2.15M) | (578.1K) | (617.13K) |
| Financing Cash Flow | 14.03M | 12.48M | 9.27M | 18.18M | 17.91M |
| Effect of Forex Changes | 0 | (4.43K) | (117) | (21.55K) | (5.22K) |
| Net Change in Cash | 9.91M | 376.64K | (3.8M) | 2.45M | (943.27K) |
| Free Cash Flow | (4.12M) | (12.1M) | (13.07M) | (15.7M) | (18.84M) |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.